Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy SEQUOIA-HCM Baseline Characteristics and Study Design
Coats C, Maron M, Abraham T, Olivotto I, Lee M, Arad M, Cardim N, Ma C, Choudhury L, Düngen H, Garcia-Pavia P, Hagège A, Lewis G, Michels M, Oreziak A, Owens A, Tfelt-Hansen J, Veselka J, Watkins H, Heitner S, Jacoby D, Kupfer S, Malik F, Meng L, Wohltman A, Masri A, Investigators S. Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy SEQUOIA-HCM Baseline Characteristics and Study Design. JACC Heart Failure 2023, 12: 199-215. PMID: 38032573, DOI: 10.1016/j.jchf.2023.10.004.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyHealth-related qualityBaseline characteristicsClinical trialsExercise capacityPhase 3 trialRisk of arrhythmiaDesign of clinical trialsContemporary managementImpaired exercise capacityStandard-of-care medicationsHealth-related quality of lifeEffects of potential therapiesHypertrophic cardiomyopathyPersistent residual symptomsHeart failureEthnically diverse populationsResidual symptomsQuality of lifePotential therapiesSudden deathPatientsMortality rateSymptom burdenFunctional capacity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply